MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Watch Listen Read
Login Nexus Watchlists Settings
  • MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Investment Compounding Calculator
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Theme Style
Switch to Dark Mode
IMCR company logo - Stock analysis and financial data

IMCR

Immunocore Holdings plc

$32.93
0.26
 (0.8%)
Exchange:   NASDAQ
Market Cap:   1.659B
Shares Outstanding:   27.307M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Bahija Jallal
Full Time Employees:  493
Address: 
92 Park Drive
Abingdon
OX14 4RY
GB
Website:  https://www.immunocore.com
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company’s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

EPS

🔒 You are currently logged out

Login
View full analyst estimates

Earnings Call

🔒 You are currently logged out

Login
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Balance Sheet

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Cash Flow Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Analyst Estimates

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Current Key Metrics

🔒 You are currently logged out

Login

Forward P/E Ratios

🔒 You are currently logged out

Login

SWOT Analysis

🔒 You are currently logged out

Login

At what price to buy it? –
Intrinsic Value Calculator

🔒 Premium Feature

Log in to access the IMCR Intrinsic Value Calculator

🔑 Log In
📝 Sign Up Free

Get comprehensive stock analysis with premium features

🔒 You are currently logged out

Login
MS_Stock_Embed class not found. Please check plugin configuration.

Relevant news

07-08-2025 07:00
Immunocore reports second quarter financial results and provides a business update